Iprindole

Iprindole is a tricyclic antidepressant that has actions and uses similar to those of AMITRIPTYLINE, but has only weak antimuscarinic and sedative effects.

Brands
Adult Dose
Neonatal
Paedriatic
Characteristics
. The Molecular Weight of Iprindole is 284.40.
Contraindications
Iprindole is contraindicated in conditions like Mania.
Effects
The severe or irreversible adverse effects of Iprindole, which give rise to further complications include Ataxia, Coma, Heart failure.The signs and symptoms that are produced after the acute overdosage of Iprindole include Tachycardia, Convulsions, Blurred vision, Urinary retention, Hypothermia, Hypoglycemia, Sweating, Hyperflexia.The symptomatic adverse reactions produced by Iprindole are more or less tolerable and if they become severe, they can be treated symptomatically, these include Drowsiness, Nausea, Constipation, Dry mouth, Rashes, Weight gain, Tremor, Convulsions.
Indications
Iprindole is primarily indicated in conditions like Depression, and can also be given in adjunctive therapy as an alternative drug of choice in Obsessive-compulsive disorders.
Interactions
Iprindole is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAdrenalineLikely interaction of IPRINDOLE increasing the HYPERTENSIVE effect of ADRENALINE. MajorAlprazolamTheoretical potential for ALPRAZOLAM increasing the SEDATIVE effect of IPRINDOLE. ModerateMay need to avoid combination.AmobarbitalTheoretical potential for AMOBARBITAL increasing the CONVULSANT effect of IPRINDOLE.ModerateMay need to avoid combination.AstemizoleTheoretical potential for IPRINDOLE increasing the ARRHYTHMOGENIC effect of ASTEMIZOLE. MajorBromazepamTheoretical potential for BROMAZEPAM increasing the SEDATIVE effect of IPRINDOLE. MajorMay need to avoid combination.Bupropion (HCl)Likely interaction of IPRINDOLE increasing the CONVULSANT effect of BUPROPION. Moderate risk.ModerateMay need to avoid combination.CarbamazepineTheoretical potential for CARBAMAZEPINE increasing the CONVULSANT effect of IPRINDOLE.ModerateChlordiazepoxide (HCl)Theoretical potential for CHLORDIAZEPOXIDE increasing the SEDATIVE effect of IPRINDOLE.ModerateClonazepamTheoretical potential for CLONAZEPAM increasing the SEDATIVE effect of IPRINDOLE. ModerateClonidine (HCl)Theoretical potential for IPRINDOLE reducing the HYPOTENSIVE effect of CLONIDINE.MajorDiazepamTheoretical potential for DIAZEPAM increasing the SEDATIVE effect of IPRINDOLE. ModerateEthosuximideTheoretical potential for ETHOSUXIMIDE increasing the CONVULSANT effect of IPRINDOLE. ModerateFenfluramine (HCl)Likely interaction of FENFLURAMINE HYDROCHLORIDE reducing the ANTIDEPRESSANT effect of IPRINDOLE.MajorMay need to avoid combinationFlurazepam (HCl)Theoretical potential for FLURAZEPAM increasing the SEDATIVE effect of IPRINDOLE. ModerateMay need to avoid combination.LoprazolamTheoretical potential for LOPRAZOLAM increasing the SEDATIVE effect of IPRINDOLE. May need to avoid combination These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Interfrence
Risks
Drug should not be given to Pregnant Mothers, patients suffering from Kidney dysfunction, and patients suffering from Liver Malfunction.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Warnings
IPRINDOLE posesses antimuscarinic activity so care should be taken in glaucoma and prostatic enlargement. Prolonged seizures have occurred following concurrent ECT. Avoid abrupt withdrawal. Withdraw IPRINDOLE gradually over several weeks. Caution in patients taking Monoamine Oxidase Inhibiting antidepressants (MAOI). IPRINDOLE may cause hypertensive crisis.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.